Scarica l'app Stockscreener
8.88
1.99%
-0.18
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché OCUL Giù?
Forum
Previsione
Precedente Chiudi:
$9.06
Aprire:
$9.19
Volume 24 ore:
2.67M
Relative Volume:
0.65
Capitalizzazione di mercato:
$1.93B
Reddito:
$61.10M
Utile/perdita netta:
$-138.36M
Rapporto P/E:
-6.5778
EPS:
-1.35
Flusso di cassa netto:
$-90.59M
1 W Prestazione:
-3.06%
1M Prestazione:
-14.86%
6M Prestazione:
-28.96%
1 anno Prestazione:
+18.72%
Intervallo 1D:
$8.83
$9.34
Intervallo di 1 settimana:
$8.6331
$9.69
Portata 52W:
$5.80
$16.44
Ocular Therapeutix Inc Stock (OCUL) Company Profile
Nome
Ocular Therapeutix Inc
Settore
Industria
Telefono
781-357-4000
Indirizzo
15 CROSBY DRIVE, BEDFORD, MA
Compare OCUL vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OCUL
Ocular Therapeutix Inc
|
8.88 | 1.97B | 61.10M | -138.36M | -90.59M | -1.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Ocular Therapeutix Inc Stock (OCUL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-15 | Iniziato | Chardan Capital Markets | Buy |
| 2025-04-08 | Iniziato | William Blair | Outperform |
| 2025-03-18 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-03-11 | Iniziato | Needham | Buy |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-06-20 | Aggiornamento | TD Cowen | Hold → Buy |
| 2024-05-31 | Ripresa | Piper Sandler | Overweight |
| 2024-02-09 | Iniziato | BofA Securities | Buy |
| 2023-04-21 | Iniziato | Robert W. Baird | Outperform |
| 2022-08-10 | Ripresa | Berenberg | Buy |
| 2021-08-10 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-12-28 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2020-12-17 | Iniziato | Berenberg | Buy |
| 2020-11-13 | Reiterato | Raymond James | Strong Buy |
| 2020-08-10 | Reiterato | H.C. Wainwright | Buy |
| 2020-03-03 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2019-05-21 | Downgrade | Cowen | Outperform → Market Perform |
| 2019-05-21 | Reiterato | H.C. Wainwright | Buy |
| 2019-05-21 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2018-12-03 | Reiterato | Cantor Fitzgerald | Overweight |
| 2018-11-15 | Iniziato | Raymond James | Strong Buy |
| 2018-09-07 | Iniziato | Piper Jaffray | Overweight |
| 2017-10-24 | Iniziato | Guggenheim | Buy |
| 2017-07-26 | Iniziato | H.C. Wainwright | Buy |
| 2017-07-12 | Reiterato | Cantor Fitzgerald | Overweight |
| 2017-06-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2017-02-10 | Iniziato | Cantor Fitzgerald | Overweight |
| 2016-11-15 | Reiterato | RBC Capital Mkts | Outperform |
| 2016-08-11 | Iniziato | JMP Securities | Mkt Outperform |
| 2016-02-17 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2015-10-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2015-08-13 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Ocular Therapeutix Inc Borsa (OCUL) Ultime notizie
Ocular Therapeutix to Host Webcast Presenting SOL-1 Data for AXPAXLI™ on February 17, 2026 - Quiver Quantitative
Ocular Therapeutix™ to Announce Topline Data for SOL-1 - GlobeNewswire
Ocular Therapeutix: Considering Their Phase 3 'Superiority' Trial's Prospect (NASDAQ:OCUL) - Seeking Alpha
Ocular Therapeutix Equity Grants Balance Growth Plans And Dilution Concerns - Yahoo Finance
Why It's Time To Keep A Close Eye On OCUL - RTTNews
Ocular Therapeutix (OCUL) Stock Analysis: A Biotech Gem With 171% Upside Potential - DirectorsTalk Interviews
How Investors Are Reacting To Ocular Therapeutix (OCUL) Revenue Miss And Widening 2025 Net Loss - Sahm
Bearish Setup: Is Ocular Therapeutix Inc gaining market shareDay Trade & Daily Stock Trend Reports - baoquankhu1.vn
Ocular Therapeutix Faces Declining Sales and Profitability Amid Market Sentiment Shift - Markets Mojo
Aug Closing: Will Ocular Therapeutix Inc stock hit new highs in YEARMarket Sentiment Summary & Consistent Return Strategy Ideas - baoquankhu1.vn
Analysts Conflicted on These Healthcare Names: Illumina (ILMN) and Ocular Therapeutix (OCUL) - The Globe and Mail
Will Ocular Therapeutix Inc stock hit new highs in YEARWeekly Risk Summary & Safe Entry Point Identification - baoquankhu1.vn
Ocular Therapeutix (NASDAQ:OCUL) Raised to Hold at Wall Street Zen - MarketBeat
(OCUL) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Globe and Mail
RBC Capital reiterates Outperform rating on Ocular Therapeutix stock By Investing.com - Investing.com Canada
Assessing Ocular Therapeutix (OCUL) Valuation After Recent Share Price Volatility - Sahm
Ocular Therapeutix Inc earnings beat by $0.03, revenue fell short of estimates - Investing.com South Africa
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Regulatory Turbulence Threatens Ocular Therapeutix: FDA Disruptions and Global Delays Raise Approval and Funding Risks - TipRanks
Ocular Therapeutix Reports Fourth Quarter and Full Year 2025 Financials, Provides Business Highlights - VisionMonday.com
Decoding Ocular Therapeutix Inc (OCUL): A Strategic SWOT Insight - GuruFocus
Ocular Therapeutix (NASDAQ:OCUL) Misses Q4 CY2025 Revenue Estimates - Finviz
Ocular Therapeutix's Recent Stock Weakness Presents Buying Opportunity, RBC Says - marketscreener.com
Ocular Therapeutix (NASDAQ:OCUL) Shares Up 8.8% on Better-Than-Expected Earnings - MarketBeat
Ocular Q4 Revenue Declines; Phase 3 Wet AMD Trial Data Expected Later This Month - Nasdaq
Ocular Therapeutix (OCUL) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Ocular Therapeutix: Q4 Earnings Snapshot - kare11.com
Ocular Therapeutix Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights - TradingView
Ocular Therapeutix: Fourth Quarter Earnings Overview - Bitget
Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights - The Manila Times
Earnings Beat: Is Ocular Therapeutix Inc stock heavily shorted2025 Momentum Check & Fast Momentum Entry Tips - baoquankhu1.vn
Ocular Therapeutix (NASDAQ:OCUL) COO Sells $51,538.90 in Stock - MarketBeat
Insider Selling: Ocular Therapeutix (NASDAQ:OCUL) COO Sells 5,455 Shares of Stock - MarketBeat
Notman, Ocular Therapeutix COO, sells $101,396 in stock By Investing.com - Investing.com Canada
Notman, Ocular Therapeutix COO, sells $101,396 in stock - Investing.com
Ocular Therapeutix Sees Unusually Large Options Volume (NASDAQ:OCUL) - MarketBeat
Ocular Therapeutix: Why SOL-1 Trial Outcome Is Likely Positive (NASDAQ:OCUL) - Seeking Alpha
Ocular Therapeutix, Inc.'s (NASDAQ:OCUL) Institutional Investors Lost 16% Last Week but Have Benefitted From Longer-term Gains - 富途牛牛
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Ocular Therapeutix Leadership Shifts And Valuation Gap Draw Investor Focus - Sahm
Ocular Therapeutix (NASDAQ:OCUL) Share Price Crosses Below 200-Day Moving AverageHere's Why - MarketBeat
Is Ocular Therapeutix Inc. undervalued by DCF analysisJuly 2025 Spike Watch & Short-Term Trading Opportunity Alerts - Mfd.ru
A Look At Ocular Therapeutix (OCUL) Valuation After Mixed Earnings And New Executive Appointments - Sahm
Is Ocular Therapeutix’s (OCUL) New Commercial Hire Quietly Reframing Its Long‑Term Strategy? - Yahoo Finance
RSI Alert: Ocular Therapeutix (OCUL) Now Oversold - Nasdaq
Ocular Therapeutix, Inc. (OCUL) Stock Analysis: Biotechnology Innovator with 122% Upside Potential - DirectorsTalk Interviews
Responsive Playbooks and the OCUL Inflection - Stock Traders Daily
A Look Back at Pharmaceuticals Stocks’ Q3 Earnings: Ocular Therapeutix (NASDAQ:OCUL) Vs The Rest Of The Pack - Yahoo Finance
Decliners Report: Is Ocular Therapeutix Inc undervalued by DCF analysisJuly 2025 Sentiment & Detailed Earnings Play Alerts - baoquankhu1.vn
Corticosteroids Market Report 2026 - GlobeNewswire Inc.
Ocular Therapeutix Inc Azioni (OCUL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.12%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):